Scleroderma News

DESTIN, Fla. — Positive results for chimeric antigen receptor T-cell therapy in systemic sclerosis and myositis have added fuel to the fire of recent landmark data in lupus, said a speaker at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Stem cell transplantation, accompanied by total body radiation, is the only “cure” for progressive systemic sclerosis currently available, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Patients with systemic sclerosis who demonstrate left ventricular abnormalities, either overt or “subclinical,” have poorer survival and increased shortness of breath, according to data published in Seminars in Arthritis and Rheumatism.

As much as 43% of patients with systemic sclerosis are malnourished, while 33% demonstrate severe malnutrition, according to data from an Australian study published in Rheumatology.

The 2022 European Society of Cardiology risk assessment tool, when applied at baseline and follow-up, can accurately predict survival in patients with systemic sclerosis-associated pulmonary arterial hypertension, according to data.

The FDA has granted orphan drug designation to BLR-200, an investigational therapy for the treatment of scleroderma, according to a press release from manufacturer.

Nearly three-quarters of patients with systemic sclerosis demonstrate symptom burden that met the threshold for needing specialist palliative care, according to data published in Arthritis Care & Research.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

The FDA has granted orphan drug designation to Cabaletta Bio’s CAR T-cell investigational therapy for the treatment of systemic sclerosis, according to a press release from the manufacturer.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.